Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Arcus Biosciences, Inc. (NYSE:RCUS) has received a consensus rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $38.55.

Several equities analysts recently commented on the company. TD Cowen started coverage on Arcus Biosciences in a research report on Wednesday, September 16th. They set a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Friday, July 17th. HC Wainwright increased their price objective on shares of Arcus Biosciences from $32.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, July 20th. William Blair initiated coverage on shares of Arcus Biosciences in a research note on Friday. They set an “outperform” rating on the stock. Finally, Wells Fargo & Company lifted their price objective on shares of Arcus Biosciences from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Thursday, August 6th.

Insider Buying and Selling at Arcus Biosciences

In other news, CAO Alexander Azoy sold 2,827 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $30.00, for a total value of $84,810.00. Following the completion of the transaction, the chief accounting officer directly owned 39,581 shares in the company, valued at approximately $1,187,430. This represents a 6.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Arcus Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC purchased a new position in Arcus Biosciences in the 2nd quarter valued at about $30,000. KBC Group NV purchased a new stake in shares of Arcus Biosciences during the first quarter worth about $50,000. GAMMA Investing LLC increased its position in shares of Arcus Biosciences by 10.0% during the second quarter. GAMMA Investing LLC now owns 3,966 shares of the company’s stock worth $122,000 after acquiring an additional 359 shares during the last quarter. Nykredit A S purchased a new stake in shares of Arcus Biosciences during the second quarter worth about $134,000. Finally, State of Wyoming acquired a new position in shares of Arcus Biosciences in the second quarter worth about $142,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Trading Up 1.1%

NYSE:RCUS opened at $22.79 on Friday. The business’s 50-day moving average is $27.09 and its two-hundred day moving average is $26.22. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.82 and a quick ratio of 3.82. Arcus Biosciences has a 12 month low of $16.04 and a 12 month high of $31.74. The firm has a market capitalization of $2.90 billion, a PE ratio of -5.84 and a beta of 0.94.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Wednesday, August 5th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.17. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%. The company had revenue of $41.00 million during the quarter, compared to the consensus estimate of $21.98 million. The company’s revenue was down 74.4% compared to the same quarter last year. Research analysts predict that Arcus Biosciences will post -3.53 earnings per share for the current fiscal year.

About Arcus Biosciences

Arcus Biosciences, Inc is a biopharmaceutical company focused on discovering and developing medicines for the treatment of cancer. The company uses a proprietary research platform to develop small-molecule and antibody-based therapies designed to target biological mechanisms involved in tumor growth and immune-system regulation.

Arcus’ oncology pipeline has included investigational therapies such as zimberelimab, an anti-PD-1 antibody; domvanalimab, an anti-TIGIT antibody; quemliclustat, a CD73 inhibitor; and etrumadenant, an adenosine receptor antagonist.